Clinical Trials

Clinical Trial for Metastatic Colorectal Cancer (CRDF-004)

Resources for
Patients and Caregivers

Cancer patients have important goals when managing their condition, which may include participation in a clinical trial with an investigational drug.

On this page, you will find resources which may be useful to you.

For more information about Cardiff Oncology’s ongoing clinical trial in metastatic colorectal cancer, please visit the CRDF-004 clinical trial website on ClinicalTrials.gov, or contact us via email at [email protected].

Please do not include any personal health information or reports/scans if submitting inquiries to [email protected].

Cardiff Oncology’s clinical trial for metastatic colorectal cancer (CRDF-004)

Cardiff Oncology has initiated a clinical trial, CRDF-004, that is being conducted at multiple sites across the United States. The purpose of this trial is to assess the safety and efficacy of our investigational drug onvansertib in combination with the current standard of care for patients with KRAS or NRAS-mutated metastatic colorectal cancer in the first-line setting.

How do I know if I can take part?

You may be able to take part in our CRDF-004 clinical trial if:

  • You have been diagnosed with metastatic colorectal cancer.
  • The cancer cells have a specific genetic mutation known as a RAS mutation. There are several types of RAS mutations including KRAS and NRAS that are eligible for enrollment in our trial.
  • You have not had previous systemic therapy, such as chemotherapy, in the metastatic setting.
  • You can discuss your eligibility for the CRDF-004 trial with your healthcare provider. The complete list of Key eligibility criteria are listed on the CRDF-004 clinical trial website on ClinicalTrials.gov.
couple-in-beach

Where is the CRDF-004 trial being conducted?

We plan to conduct the trial at around 30 sites across the United States.

Learning more about the CRDF-004 trial

For more information about Cardiff Oncology’s ongoing clinical trial in metastatic colorectal cancer, CRDF-004, you can: